Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative - Top-Institutions - MDSpire

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative

  • By

  • Yirui Wei

  • Mengyuan Wang

  • Yong Huang

  • Lu Gan

  • Kangjie Li

  • Yifeng Li

  • Zhaoyang Li

  • Qiao Cheng

  • May 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Netherlands Cancer Institute
    Netherlands Cancer Institute

    Amsterdam, North Holland

    Key Differentiators

    • Oncology

  • #2

    University of Padua
    University of Padua

    Padua, Veneto

    Key Differentiators

    • Oncology

  • #3

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative

  • by Yirui Wei, Mengyuan Wang, Yong Huang, Lu Gan, Kangjie Li, Yifeng Li, Zhaoyang Li, Qiao Cheng

  • May 8, 2026

Related Content

Effects of SOX10 on the proliferative, invasive, migratory, and epithelial–mesenchymal transition abilities of triple-negative breast cancer cells

Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial

Editorial: Epigenetic modulation in cancer